The inhibition of endotoxin-induced local inflammation by LDH virus or LDH virus-infected tumors is mediated by interferon.
The footpad swelling reaction induced by local injection of S. marcescens lipopolysaccharide was found to be inhibited in mice given a transplantable tumor (TA3) or cell-free ascitic fluid from tumor-bearing mice. The tumor was shown to contain LDH virus, which is known to cause inapparent persistent infections in mice. Monoclonal antibodies directed against protein VP3 of the LDH virus could partially abrogate the anti-inflammatory effect of the TA3-ascitic fluid, and, conversely, the anti-inflammatory effect could be obtained by LDH virus isolated from the tumor and reproduced by serial passage of cell-free fluids. Inhibition of the footpad reaction was seen in the acute but not in the chronic phase of LDH virus infection, suggesting that the anti-inflammatory effect might be due to endogenous interferon (IFN) which, similarly, was only detectable in the acute phase. Newcastle disease virus, another potent interferon inducer, had a similar inhibitory effect on the footpad reactivity. Moreover, the inhibitory effect of LDH virus infection could partially be abrogated by administration of a polyclonal antibody directed against murine IFN-alpha,beta. Finally, passively administered natural murine IFN-alpha,beta or recombinant murine IFN-alpha 1 (but not recombinant murine IFN-beta) was found to cause inhibition of the footpad reaction. Since Gram-negative bacteria and their lipopolysaccharides have the ability to induce a systemic interferon response, our findings suggest that this interferon may play a modulatory role in local inflammation caused by these bacteria. Our findings also open a new perspective for interferon therapy of certain inflammatory reactions to bacterial infections.
D000818:Animals; D005260:Female; D007106:Immune Sera; D007249:Inflammation; D007370:Interferon Type I / Q000627:therapeutic use*; D007700:Kinetics; D008070:Lipopolysaccharides; D051379:Mice; D008815:Mice, Inbred Strains; D009374:Neoplasms, Experimental / Q000503:physiopathology* / Q000628:therapy; D011994:Recombinant Proteins / Q000627:therapeutic use*; D012706:Serratia marcescens; D014036:Togaviridae Infections / Q000503:physiopathology* / Q000628:therapy
D007106:Immune Sera; D007370:Interferon Type I; D008070:Lipopolysaccharides; D011994:Recombinant Proteins